- Home
- AUPH vs APLT Comparison
AUPH vs APLT Comparison
Compare AUPH & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- APLT
- Stock Information
- Founded
- AUPH 1993
- APLT 2016
- Country
- AUPH Canada
- APLT United States
- Employees
- AUPH N/A
- APLT N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- APLT Health Care
- Exchange
- AUPH Nasdaq
- APLT Nasdaq
- Market Cap
- AUPH 1.4B
- APLT 178.6M
- IPO Year
- AUPH 1999
- APLT 2019
- Fundamental
- Price
- AUPH $11.55
- APLT $1.28
- Analyst Decision
- AUPH Strong Buy
- APLT Buy
- Analyst Count
- AUPH 2
- APLT 5
- Target Price
- AUPH $13.00
- APLT $4.13
- AVG Volume (30 Days)
- AUPH 1.7M
- APLT 12.5M
- Earning Date
- AUPH 11-06-2025
- APLT 11-06-2025
- Dividend Yield
- AUPH N/A
- APLT N/A
- EPS Growth
- AUPH N/A
- APLT N/A
- EPS
- AUPH 0.42
- APLT N/A
- Revenue
- AUPH $260,111,000.00
- APLT $121,000.00
- Revenue This Year
- AUPH $17.33
- APLT N/A
- Revenue Next Year
- AUPH $14.31
- APLT $5,935.35
- P/E Ratio
- AUPH $27.48
- APLT N/A
- Revenue Growth
- AUPH 25.59
- APLT N/A
- 52 Week Low
- AUPH $6.55
- APLT $0.30
- 52 Week High
- AUPH $13.54
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- AUPH 47.06
- APLT 68.44
- Support Level
- AUPH $10.92
- APLT $0.90
- Resistance Level
- AUPH $11.72
- APLT $1.28
- Average True Range (ATR)
- AUPH 0.41
- APLT 0.16
- MACD
- AUPH -0.02
- APLT 0.03
- Stochastic Oscillator
- AUPH 65.45
- APLT 95.13
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.